Phenotype of podoplanin-positive cells in the fibrotic tissue. Maria Cimini Antonio Cannatá Gianandrea Pasquinelli Marcello Rota Polina Goichberg 10.1371/journal.pone.0173927.g003 https://plos.figshare.com/articles/figure/Phenotype_of_podoplanin-positive_cells_in_the_fibrotic_tissue_/4782253 <p>Thin cardiac sections were indirectly immunolabeled with antibodies that recognize podoplanin (red) and either fibronectin and vimentin (<b>A</b>; green and grey, respectively), VEGFR-2 and CD34 (<b>B</b> and <b>C</b>; green and grey, respectively), or α-SMA (<b>D</b>; grey). Nuclei, blue. Time after MI is indicated. Areas in rectangles are shown at higher magnifications in the adjacent images for each color channel. Note that vimentin (<b>A</b>) or α-SMA (<b>D</b>) labeling is rarely detectable in podoplanin-expressing cells (examples are pointed by yellow arrowheads). In <b>B</b> and <b>C</b>, the podoplanin-presenting cells show minimal VEGFR-2 labeling. At 2 days after MI, the podoplanin-bearing cells mostly do not co-stain with CD34 (exemplified by yellow arrowheads). Starting 2 weeks after MI, the CD34 staining is present in irregular capillary-like structures (examples are indicated by white arrows). In <b>C</b>, quantitative image analysis demonstrating changes in the podoplanin co-labeling with CD34 at indicated times after MI is included in the graph (lower panel). Data represent mean and SD of the co-localization coefficient; n = 5–6 image fields per group. By one-way ANOVA, *P < 0.02 for 2 weeks vs. 2 days; **P < 0.0001 for 1 month vs. 2 days; ns, not-significant for 1 month vs. 2 weeks.</p> 2017-03-23 18:02:48 lymphatic network scar development artery ligation lymphatic vessel growth sham-operated counterparts lymphatic endothelium Podoplanin-carrying populations Podoplanin immunoreactivity infarcted adult heart infarcted myocardium podoplanin-containing cells infarcted heart mesenchymal markers infarcted hearts infarcted region scar formation VEGFR -3 podoplanin-expressing cell populations podoplanin-labeled cells spatiotemporal changes extracellular matrix deposits LYVE -1-negative cells fibrogenic responses VEGFR -2 content blood vessels podoplanin-positive cell compartment post-MI lymphangiogenesis mouse model wound granulation infarcted myocardium Cardiac lymphatic vasculature LYVE -1-positive lymphatic vessels pro-fibrotic cells master regulator PDGFR fibrotic area hematoendothelial epitope CD 34. podoplanin-presenting cells podoplanin-rich LYVE -1-negative multicellular assemblies Prox -1-positive